---
title: "Obefazimod (ABX464) in Ulcerative colitis: Average sales price and wholesale acquisition cost"
description: "Formulary evidence on Obefazimod (ABX464) in Ulcerative colitis: Average sales price and wholesale acquisition cost. Topics: Analyst assumption of a net annual U.S. price at launch of US$78,000 (LifeSci Capital, June 2026). 1 evidence topic quoted from 1 source."
canonical: "https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/product-information-and-disease-description/average-sales-price-and-wholesale-acquisition-cost"
published: "2026-11-18T10:42:55-05:00"
modified: "2026-11-18T10:42:55-05:00"
---

# Obefazimod (ABX464) in Ulcerative colitis: Average sales price and wholesale acquisition cost

<a id="heading-2.1.2.3"></a>

## 2.1.2.3 Average Sales Price and Wholesale Acquisition Cost

<a id="topic-2.1.2.3-1"></a>

### Wholesale acquisition cost and average sales price

Not applicable.

<a id="topic-2.1.2.3-2"></a>

### Analyst assumption of a net annual U.S. price at launch of US$78,000 (LifeSci Capital, June 2026)

> “We currently assume a 90% probability of success with a net annual price at launch of US$78,000 in the U.S.”
> “increased from US$66,000 prior based on recent management commentary”

Source: [Streetwise Reports (2026)](https://www.streetwisereports.com/article/2026/07/01/clinical-stage-biotech-discloses-colitis-retreatment-results-gets-mixed-ratings.html)

## Related pages
- [Obefazimod (ABX464): Ulcerative colitis](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Terms and abbreviations](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/terms-and-abbreviations.md)
- [Obefazimod (ABX464): Ulcerative colitis](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/executive-summary.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Product information and disease description](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/product-information-and-disease-description.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Clinical evidence](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/clinical-evidence.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Economic information and modeling report](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/economics) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/economics.md)
- [Obefazimod (ABX464) in Ulcerative colitis: References](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/references) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/references.md)
